Drug-drug interactions mediated by cytochrome P450 enzymes: the role of inducers and inhibitors. Clin Ther. 2013;35:797–810. Google Scholar Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6’,7’-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab ...
Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P‐Glycoprotein Inhibitor (Itraconazole)rovatirelinTRH analogdrug‐drug interactionitraconazoleCYP3A4/5multidrug resistance transporter 1P‐glycoprotein...
This is the case for the lopinavir/ritonavir protease inhibitor cocktail, in which ritonavir boosts the plasma level of the active drug (lopinavir) by acting as a CYP3A4 inhibitor (35). The greatest risk of intoxication, however, may still come from the uncontrolled dosing associated with ...
A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma. J Clin Oncol 2013; 31: Abstract 2555....
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012;32(2):150-158.Kellerman D, Kori S, Forst A, et al .: Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine...
for methods of treating a patient with a\nCYP3A4 substrate drug contraindicated for\nconcomitant administration with a strong CYP3A4 inhibitor, wherein the patient\nis treated with multiple doses of posaconazole, stops\nposaconazole treatment, and then is treated with the CYP3A4 substrate drug. ...
for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In...
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012;32(2):150-158.Kellerman D, Kori S, Forst A, et al .: Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine...
It is based on two characteristic parameters: the contribution ratio (CR; i.e., the fraction of victim drug clearance by CYP) and the inhibition ratio (IR) of the inhibitor. Knowledge of these parameters allows forecasting of the ratio between the area under the plasma concentration-time ...
Drug-drug interactions mediated by cytochrome P450 enzymes: the role of inducers and inhibitors. Clin Ther. 2013;35:797–810. 10. Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6',7'- dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996...